Svaton Martin, Drosslerova Marie, Fischer Ondrej, Marel Miloslav, Hrnciarik Michal, Venclicek Ondrej, Zuna Petr, Svoboda Michal, Blazek Jiri, Bratova Monika, Mullerova Andrea, Vankova Bohuslava, Krejci Daniel
Department of Pneumology and Phthisiology, University Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Department of Respiratory Medicine, Thomayer Hospital, Prague, Czech Republic.
Transl Cancer Res. 2022 Sep;11(9):3017-3023. doi: 10.21037/tcr-22-260.
Programmed death-ligand 1 (PD-L1) expression is a standard predictor in the selection of immunotherapy for locally advanced/advanced non-small cell lung cancer (NSCLC). However, comedication with corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) may influence the effectiveness of this treatment as documented in several previous studies. Due to certain molecular linkages between PD-L1 and corticosteroids or NSAIDs, we therefore addressed the question of whether there is a relationship between PD-L1 expression in NSCLC and the use of this comedication.
This is a retrospective study using the Czech tumor registry LUng CAncer focuS (LUCAS), from which patient data were drawn. Independence of two categorical parameters was tested by Pearson's chi-square test.
In our group of 1,148 patients, we observed no significant relationship between PD-L1 expression and the use of corticosteroids or NSAIDs.
According to our data, treatment with corticosteroids or NSAIDs during biopsy does not affect the expression of PD-L1 and it is therefore not necessary to take this treatment into account in this regard.
程序性死亡配体1(PD-L1)表达是局部晚期/晚期非小细胞肺癌(NSCLC)免疫治疗选择中的一项标准预测指标。然而,如先前多项研究所记录,同时使用皮质类固醇或非甾体抗炎药(NSAIDs)可能会影响这种治疗的效果。由于PD-L1与皮质类固醇或NSAIDs之间存在某些分子联系,因此我们探讨了NSCLC中PD-L1表达与这种联合用药之间是否存在关联的问题。
这是一项使用捷克肿瘤登记处肺癌聚焦(LUCAS)进行的回顾性研究,从中提取患者数据。通过Pearson卡方检验来检验两个分类参数的独立性。
在我们的1148例患者组中,我们未观察到PD-L1表达与皮质类固醇或NSAIDs的使用之间存在显著关联。
根据我们的数据,活检期间使用皮质类固醇或NSAIDs治疗不会影响PD-L1的表达,因此在这方面无需考虑这种治疗。